3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Breast Neoplasms
1
Interventions
fludarabine phosphate
6
Rituximab
5
Antilymphocyte Serum
5
Tacrolimus
4
Cyclophosphamide
4
pegaspargase
3
Whole-Body Irradiation
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Oxaliplatin
3
Mycophenolic Acid
3
Etoposide
3
Dasatinib
3
Vincristine
2
Melphalan
2
Lenalidomide
2
Gemcitabine
2
Filgrastim
2
Doxorubicin
2
Busulfan
2
tislelizumab
1
thymoglobulin
1
tanespimycin
1
plerixafor
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
obatoclax
1
gemcitabine-oxaliplatin regimen
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Extranodal NK-T-Cell
×
Ice
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled